Next Article in Journal
Supercritical CO2 Extraction of Phytocompounds from Olive Pomace Subjected to Different Drying Methods
Previous Article in Journal
CytroCell: Valued Cellulose from Citrus Processing Waste
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 26
Issue 3
10.3390/molecules26030597
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Stereoselective Synthesis of Oxazolidin-2-ones via an Asymmetric Aldol/Curtius Reaction: Concise Total Synthesis of (−)-Cytoxazone

by
Hosam Choi
,
Hanho Jang
,
Joohee Choi
and
Kiyoun Lee
*
Department of Chemistry, The Catholic University of Korea, Bucheon 14662, Korea
*
Author to whom correspondence should be addressed.
Molecules 2021, 26(3), 597; https://doi.org/10.3390/molecules26030597
Submission received: 13 January 2021 / Revised: 20 January 2021 / Accepted: 21 January 2021 / Published: 23 January 2021
(This article belongs to the Section Organic Chemistry)
Browse Figures
Versions Notes

Abstract

:
Herein, we are reporting an efficient approach toward the synthesis of 4,5-disubstituted oxazolidin-2-one scaffolds. The developed approach is based on a combination of an asymmetric aldol and a modified Curtius protocol, which uses an effective intramolecular ring closure to rapidly access a range of oxazolidin-2-one building blocks. This strategy also permits a straightforward and concise asymmetric total synthesis of (−)-cytoxazone. Consisting of three steps, this is one of the shortest syntheses reported to date. Ultimately, this convenient platform would provide a promising method for the early phases of drug discovery.

1. Introduction

Functionalized oxazolidin-2-ones are among the most interesting heterocyclic compounds, with uses both as pharmaceuticals and as key synthetic intermediates (Scheme 1a). Since the seminal discovery of anti-bacterial activity of certain oxazolidin-2-ones by EI DuPont de Nemours and Co., Inc. in 1987 [1], the synthesis of substituted oxazolidin-2-one motifs has drawn a considerable amount of interest from the synthetic community [2,3]. These functionalized oxazolidin-2-one compounds have demonstrated a wide spectrum of pharmacological properties [4,5,6]. For instance, linezolid (LZD), the first synthetic oxazolidin-2-one antimicrobial agent, has shown potent efficacy against Gram-positive bacteria through the inhibition of bacterial protein synthesis [7,8]. LZD was approved by the FDA for the treatment of a range of traditionally drug-resistant infections, including MRSA and drug-resistant tuberculosis in 2002 [9]. Tedizolid is also a promising antibacterial agent that is used to treat skin infection in adults [10]. Thanks for these pharmacological properties, structurally diverse oxazolidin-2-one motifs often serve as key synthetic intermediates within the context of macrolide antibiotics syntheses. Additionally, these cyclic carbamate moieties are one of the most significant and widely utilized chiral auxiliaries in the realm of organic synthesis [11,12,13].
Due to the amount of intrigue surrounding the unique structural features and diverse therapeutic utility, in the past decades, great emphasis has been placed on the development of synthetic approaches toward the enantioselective construction of oxazolidin-2-one moieties. There are several conventional approaches for the construction of oxazolidin-2-ones. One of the most common methods involves the intermolecular reaction of a β-amino alcohol with phosgene (Scheme 1b) [14,15].
However, these types of method suffer from limited availability of starting materials, in some cases, due to the need for a pre-installed stereogenic center on the β-amino alcohol prior to ring closure. Alternative common strategies include the reaction of isocyanates with epoxides and the reaction of aziridines with carbon dioxide [16,17,18]. Despite these advances in the field of oxazolidin-2-one synthesis, successful methods are thus far largely limited in terms of the access to substrates, regio- and stereochemical outcome, ability to increase molecular complexity of easily obtainable starting materials, and sufficiently mild reaction conditions that are compatible with various functional groups. Furthermore, to date, the asymmetric synthesis of oxazolidin-2-one motifs has thus far remained out of reach. More specifically, many asymmetric strategies reported to have focused on the generation of C4- or C5-monosubstituted oxazolidinones, while strategies providing access to oxazolidinones possessing 4,5-two vicinal stereogenic centers have rarely been reported. These aspects have resulted in the continuous demand for new synthetic approaches for the construction of optically active oxazolidin-2-one moieties.
To meet this synthetic need, herein we disclose studies on the development of an efficient synthesis of oxazolidin-2-one scaffolds with access to 4,5-vicinal stereogenic centers, which uses a combination of an asymmetric aldol and a modified Curtius procedure to undergo an effective intramolecular cyclization. This convenient platform consequently permitted the concise total synthesis of natural (−)-cytoxazone (1) in only three steps. To the best of our knowledge, this work presents the shortest asymmetric total synthesis of (−)-cytoxazone reported to date.
The Curtius approach most commonly involves the isolation of acyl azides from carboxylic acid derivatives such as acyl chlorides or mixed anhydrides [19,20,21]. However, the acid chloride itself often raises the issue of compatibility with acid-labile functionalities and has additional drawbacks such as issues with preparation and storage. Alternative one-pot protocols for the synthesis of carbarmates from carboxylic acids by employing the diphenylphosphoryl azide (DPPA) have been more attractive [22,23]. Though quite efficient, toxicity issues and purification difficulties have been inescapable, resulting in restriction of scope and consequently, synthetic utility.

2. Results and Discussion

Keeping these considerations in mind, we were interested in the direct conversion of chiral imides to cyclic carbamates without the isolation of highly reactive acyl chlorides and/or unstable acyl azides. As illustrated in Scheme 1c, we envisaged that efficient, direct, and even diastereoselective construction of an optically active 4,5-disubstituted oxazolidin-2-one motif would be possible if a chiral auxiliary-mediated asymmetric aldol reaction was utilized in conjunction with the Curtius rearrangement, followed by in situ intramolecular ring closure in a tandem manner.
In terms of the simplified reaction mechanism, upon treatment with sufficiently nucleophilic azide transfer reagents, the chiral auxiliary bearing starting material I could be converted into acyl azide intermediate II. Subsequent thermal decomposition results in the formation of an acyl nitrene with the loss of N2, followed by the molecular rearrangement to generate the desired chiral oxazolidin-2-one, presumably through the intramolecular ring closure of the isocyanate intermediate III.
In order to test this hypothesis, syn-aldol adduct 3a was prepared as a model substrate by employing an Evans type auxiliary-mediated aldol protocol [11,24,25,26] following the procedure described by Crimmins [27,28,29] (Scheme 2). Initially, we attempted the direct nucleophilic azidation/Curtius reaction by treatment of 3a with Bu3SnN3 (3 equiv., THF, 90 °C). To our disappointment, the reaction only produced a trace amount (less than 2%) of product 4 (entry 1). Introducing an oxazolidinethione in syn-aldol product 3b and ensuing subjection in the nucleophilic azide transfer/Curtius reaction improved the yield, but only to 13% (entry 2).
These low conversions could be attributed to the inherent electrophilic nature of C1 carbonyl carbon in 3a–c and the associated inhibition of the initial acyl azide formation. Therefore, we envisioned that corresponding aldol precursors with diminished electrophilicity at C1 in auxiliaries would potentially be more productive than oxazolidinones or oxazolidinethiones in establishing more effective construction of the oxazolidin-2-ones [29,30]. Consistent with our expectation, the nucleophilic azidation/Curtius reaction of thiazolidinethione 3c under the same reaction conditions (Bu3SnN3, THF, 90 °C) proceeded to provide corresponding oxazolidin-2-one 4 in higher conversion (57%).
Encouraged by this promising result, we contemplated a series of alternative chiral auxiliaries and several N3 transfer reagents and ultimately found that a combination of the use of asymmetric syn-aldol products bearing N-acylthiazolidinethione with a Bn or an i-Pr moiety and treatment with Me3SiN3 [31] (3 equiv., THF, 90 °C, entry 9) proved to be highly effective and cleanly afforded the corresponding oxazolidin-2-one 4 in superb conversion (89%). Optimization of the solvent system revealed that THF was the best solvent of those examined (entries 9–12). The use of higher reaction concentrations (0.2 M) or prolonged reaction times (12 h) did not further improve the already excellent yield. It is worth mentioning that the developed protocol proceeds with complete retention of the enantiomeric excess and the diastereoselectivity in 4 (see Supplementary Material). Alternative nucleophilic azide transfer reactions (M2Al-N3/THF or (n-Bu)4NN3/THF) were also successful, but afforded 4 in lower conversions (Scheme 2, entries 4–6, 13–15). However, reactions that employed NaN3 proved ineffective in all tested solvent systems (DMF, MeCN, and acetone) (entries 16–18).
To gain further insight into the effect of thiazolidinethione moiety in compound 3c, we next sought to address the reactivity with a simpler ester functionality (Scheme 3). To this end, methyl ester 5 was prepared by methanolysis of 3c (DMAP (20 mol%), MeOH (1.5 equiv.), CH2Cl2, 25 °C) and subsequent azidation/Curtius reaction in the presence of Me2AlN3 gave the oxazolidin-2-one 4 in low yield (23%). Surprisingly, the azidation/Curtius reactions of 5 with the treatment of Me3SiN3, Bu3SnN3, or (n-Bu)4NN3 failed to provide the corresponding 4, but rather only resulted in no reactivity for the former and significant decomposition for the latter two cases. Subsequently, carboxylic acid 6 was also evaluated by the treatment of DPPA (Et3N, benzene, reflux), which proceeded to provide 4 in 84%, suggesting that a direct mode of oxazolidin-2-one formation from a substrate such as 3c may constitute a more effective approach than a multi-step process.
Having achieved optimal reaction conditions, we set out to explore the scope and the limitations of this transformation (Scheme 4). A series of β-hydroxy carbonyl substrates bearing aryl and aliphatic substituents were synthesized and found to react well to afford the desired 4,5-disubstituted oxazolidin-2-ones in good to excellent conversions. Electron-neutral and electron-rich aryl motifs, such as p-chlorophenyl (7a), p-fluorophenyl (7b), p-methoxyphenyl (7e), and thiophene (7c) groups, readily proceeded to provide the desired products 8a–c and 8e (90–97%). Substrates with strong electron withdrawing functionalities, such as p-cyano (7h), p-nitro (7i), and p-trifluoromethyl (7j) were also tolerated to generate the corresponding oxazolidin-2-ones (8h–8j, 79–80%). In addition, expanding the scope to aliphatic substituents (7k and 7l) proved to be feasible and provided the corresponding products 8k and 8l (73–90%), demonstrating excellent compatibility with a range of functional groups.
To demonstrate the synthetic utility of the present methodology, we tackled the synthesis (−)-cytoxazone (1). (−)-Cytoxazone was originally isolated from cultures of Streptomyces sp. in 1998 by Osada and co-workers [32]. Structural elucidation and relative stereochemistry was established by a combination of high-resolution mass spectroscopy and two-dimensional-NMR studies, while the absolute configuration was secured via the comparison of CD spectra with authentic samples, as well as the enantioselective synthesis by Nakata and co-workers [33]. It was reported that (−)-cytoxazone exhibited a cytokine modulator effect via the signaling pathway of Th2 cells (type 2 cytokines), which is involved in cell growth and differentiation [34]. These interesting pharmacological properties made this natural product and its analogs important targets for chemical synthesis, resulting in more than thirty to date [35,36,37,38,39].
Our synthesis of (−)-cytoxazone (1) is illustrated in Scheme 5. An asymmetric aldol addition of chlorotitanium enolate of 9 upon treatment with 2-benzyloxyacetaldehyde 10 furnished the syn-aldol adduct 11 in 98% yield (dr 3:1). Subsequent nucleophilic azidation/Curtius reaction of the resulting 11 in the presence of trimethylsilyl azide (3 equiv., THF, 90 °C, 5 h) smoothly proceeded to afford the desired cyclic carbamate 12 in 87% yield as a single diastereomer. Attempts with other methods (Bu3SnN3 or (n-Bu)4NN3, 3 equiv., THF, 90 °C) were also successful but afforded 12 in lower conversions (11–17%). Lastly, removal of benzyl group (Pd/C, H2, EtOH) allowed the completion of the synthesis of (−)-cytoxazone (1), whose properties proved identical in all respects with those of an authentic sample of the natural product.

3. Experimental Section

3.1. General Information

All reactions were conducted in oven-dried glassware under nitrogen. Unless otherwise stated, all reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA), Acros, or Fisher (Hampton, NH, USA), and were used without further purification. All solvents were ACS grade or better and used without further purification. Analytical thin layer chromatography (TLC) was performed with glass backed silica gel (60 Å) plates with fluorescent indication (Whatman, St. Louis, MO, USA). Visualization was accomplished by UV irradiation at 254 nm and/or by staining with ninhydrin, phosphomolybdic acid (PMA) solution, or p-anisaldehyde solution. Flash column chromatography was performed by using silica gel (particle size 70–230 mesh ASTM). All 1H-NMR and 13C-NMR spectra were recorded at 298 K on a Bruker Avance III HD 500 MHz (Bruker Corporation, Billerica, MA, USA) spectrometer in CDCl3 by using the signal of residual CHCl3, as an internal standard. All-NMR δ values are given in ppm, and all J values are in Hz. Optical rotation values were measured with a Rudolph Research Analytical (AUTOPOL II, Hackettstown, NJ, USA) polarimeter.

3.2. Representative Procedure for the Synthesis of 4 

(4S,5R)-4-methyl-5-phenyloxazolidin-2-one (4): A solution of (2S,3S)-3-hydroxy-1-((S)-4-isopropyl-2-thioxothiazolidin-3-yl)-2-methyl-3-phenylpropan-1-one 3c (38.9 mg, 0.120 mmol, 1.0 equiv.) in THF (1.2 mL, 0.1 M) was treated with Me3SiN3 (47.0 μL, 0.360 mmol, 3.0 equiv.) and the resulting mixture was heated to reflux at 90 °C. After stirring for 5 h at 90 °C, the resulting mixture was cooled to 25 °C, quenched with the addition of H2O, and diluted with CH2Cl2. The layers were separated, and the aqueous layer was extracted with CH2Cl2. The combined organic layers were washed with saturated aqueous NaCl, dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by column chromatography (SiO2, gradient eluent: 25–75% EtOAc/hexane) to provide (4S,5R)-4-methyl-5-phenyloxazolidin-2-one 4 (19.0 mg, 89%) as a white powder: [α]D25 –165 (c 0.60, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 7.35–7.40 (m, 2H), 7.31–7.34 (m, 1H), 7.27–7.29 (m, 2H), 6.79 (br s, 1H), 5.70 (d, J = 8.1 Hz, 1H), 4.18–4.24 (m, 1H), 0.80 (d, J = 6.6 Hz, 3H); 13C-NMR (125 MHz, CDCl3) δ 159.8, 134.9, 128.4, 128.3, 125.8, 80.9, 52.3, 17.4; HRMS (Q–TOF) m/z 178.0874 [(M + H)+, C10H12NO2 requires 178.0868].

3.3. Synthesis of Oxazolidin-2-one (8a–8l)

A solution of 7a–7l (1.0 equiv.) in THF (0.1 M) was treated with Me3SiN3 (3.0 equiv.) and the resulting mixture was heated to reflux at 90 °C. After stirring for 5 h at 90 °C, the resulting mixture was cooled to 25 °C, quenched with the addition of H2O, and diluted with CH2Cl2. The layers were separated, and the aqueous layer was extracted with CH2Cl2. The combined organic layers were washed with saturated aqueous NaCl, dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by column chromatography (SiO2, gradient eluent: 25–75% EtOAc/hexane) to provide 8a–8l.
(4S,5R)-5-(4-chlorophenyl)-4-methyloxazolidin-2-one (8a): A white solid: [α]D25 –124 (c 0.72, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 7.37 (d, J = 8.5 Hz, 2H), 7.23 (d, J = 8.4 Hz, 2H), 6.32 (br s, 1H), 5.68 (d, J = 8.0 Hz, 1H), 4.17–4.23 (m, 1H), 0.81 (d, J = 6.5 Hz, 3H); 13C-NMR (125 MHz, CDCl3) δ 159.3, 134.4, 133.4, 128.8, 127.3, 80.3, 52.2, 17.5; HRMS (Q–TOF) m/z 212.0484 [(M + H)+, C10H11ClNO2 requires 212.0478].
(4S,5R)-5-(4-fluorophenyl)-4-methyloxazolidin-2-one (8b): A white solid: [α]D25 –104 (c 0.27, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 7.26–7.30 (m, 2H), 7.09 (td, J = 8.7, 2.5 Hz, 2H), 5.87 (br s, 1H), 5.70 (d, J = 7.9 Hz, 1H), 4.17–4.23 (m, 1H), 0.81 (d, J = 6.5 Hz, 3H); 13C-NMR (125 MHz, CDCl3) δ 162.7 (d, J = 245.8 Hz), 159.1, 130.6 (d, J = 3.2 Hz), 127.7 (d, J = 8.2 Hz), 115.6 (d, J = 21.6 Hz), 80.4, 52.3, 17.5; HRMS (Q–TOF) m/z 196.0779 [(M + H)+, C10H11FNO2 requires 196.0774].
(4S,5R)-4-methyl-5-(thiophen-2-yl)oxazolidin-2-one (8c): A white oil: [α]D25 –33.3 (c 0.09, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 7.34 (dd, J = 4.9, 1.3 Hz, 1H), 7.02–7.07 (m, 2H), 5.92 (d, J = 7.8 Hz, 1H), 5.57 (br s, 1H), 4.17–4.24 (m, 1H), 1.00 (d, J = 6.5 Hz, 3H); 13C-NMR (125 MHz, CDCl3) δ 158.5, 137.1, 126.9, 126.1, 125.9, 78.2, 52.6, 17.0; HRMS (Q–TOF) m/z 184.0439 [(M + H)+, C8H10NO2S requires 184.0432].
(4S,5R)-5-(4-(benzyloxy)-3-methoxyphenyl)-4-methyloxazolidin-2-one (8d): A white oil: [α]D25 –50.0 (c 0.20, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 7.43 (d, J = 7.2 Hz, 2H), 7.35–7.39 (m, 2H), 7.29–7.33 (m, 1H), 6.89 (d, J = 8.3 Hz, 1H), 6.85 (d, J = 1.9 Hz, 1H), 6.74 (dd, J = 8.3, 1.9 Hz, 1H), 5.65 (d, J = 7.9 Hz, 1H), 5.44 (br s, 1H), 5.16 (s, 2H), 4.11–4.17 (m, 1H), 3.90 (s, 3H), 0.83 (d, J = 6.5 Hz, 3H); 13C-NMR (125 MHz, CDCl3) δ 159.0, 149.7, 148.2, 136.8, 128.6, 127.9, 127.7, 127.3, 118.4, 113.7, 109.4, 80.9, 71.0, 56.1, 52.5, 17.5; HRMS (Q–TOF) m/z 314.1393 [(M + H)+, C18H20NO4 requires 314.1392].
(4S,5R)-5-(4-methoxyphenyl)-4-methyloxazolidin-2-one (8e): A white solid: [α]D25 –87.4 (c 0.24, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 7.21 (d, J = 8.7 Hz, 2H), 6.91 (d, J = 8.7 Hz, 2H), 5.79 (br s, 1H), 5.67 (d, J = 7.9 Hz, 1H), 4.13–4.20 (m, 1H), 3.82 (s, 3H), 0.82 (d, J = 6.5 Hz, 3H); 13C-NMR (125 MHz, CDCl3) δ 159.7, 159.4, 127.3, 126.8, 113.9, 80.9, 55.3, 52.5, 17.5; HRMS (Q–TOF) m/z 208.0980 [(M + H)+, C11H14NO3 requires 208.0974].
(4S,5R)-5-(7-methoxybenzo[d][1,3]dioxol-5-yl)-4-methyloxazolidin-2-one (8f): A colorless oil: [α]D25 –122 (c 0.24, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 6.48 (d, J = 1.1 Hz, 1H), 6.45 (d, J = 1.1 Hz, 1H), 5.99 (s, 2H), 5.82 (br s, 1H), 6.11 (d, J = 7.9 Hz, 1H), 4.11–4.17 (m, 1H), 3.90 (s, 3H), 0.86 (d, J = 6.5 Hz, 3H); 13C-NMR (125 MHz, CDCl3) δ 159.1, 149.1, 143.7, 135.2, 129.2, 105.5, 101.7, 100.2, 80.8, 56.7, 52.5, 17.4; HRMS (Q–TOF) m/z 252.0876 [(M + H)+, C12H14NO5 requires 252.0872].
(4S,5R)-4-methyl-5-(3,4,5-trimethoxyphenyl)oxazolidin-2-one (8g): A colorless oil: [α]D25 –53.8 (c 0.39, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 6.49 (s, 2H), 5.86 (br s, 1H), 5.65 (d, J = 7.9 Hz, 1H), 4.13–4.19 (m, 1H), 3.86 (s, 6H), 3.85 (s, 3H), 0.86 (d, J = 6.5 Hz, 3H); 13C-NMR (125 MHz, CDCl3) δ 159.2, 153.4, 137.8, 130.3, 102.8, 80.9, 60.9, 56.2, 52.5, 17.4; HRMS (Q–TOF) m/z 268.1186 [(M + H)+, C13H18NO5 requires 268.1185].
4-((4S,5R)-4-methyl-2-oxooxazolidin-5-yl)benzonitrile (8h): A white solid: [α]D25 –160 (c 0.05, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 7.72 (d, J = 8.4 Hz, 2H), 7.44 (d, J = 8.2 Hz, 2H), 5.75 (d, J = 7.9 Hz, 1H), 5.61 (br s, 1H), 4.23–4.29 (m, 1H), 0.81 (d, J = 6.5 Hz, 3H); 13C-NMR (125 MHz, CDCl3) δ 158.3, 140.1, 132.4, 126.7, 118.2, 112.6, 79.9, 52.0, 17.6; HRMS (Q–TOF) m/z 203.0829 [(M + H)+, C11H11N2O2 requires 203.0821].
(4S,5R)-4-methyl-5-(4-nitrophenyl)oxazolidin-2-one (8i): A white solid: [α]D25 –225 (c 0.04, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 8.27 (dd, J = 7.0, 1.8 Hz, 2H), 7.51 (d, J = 8.6 Hz, 2H), 5.81 (d, J = 8.0 Hz, 1H), 5.68 (br s, 1H), 4.26–4.33 (m, 1H), 0.83 (d, J = 6.5 Hz, 3H); 13C-NMR (125 MHz, CDCl3) δ 158.3, 148.1, 142.0, 126.9, 123.9, 79.7, 52.0, 17.7; HRMS (Q–TOF) m/z 223.0723 [(M + H)+, C10H11N2O4 requires 223.0719].
(4S,5R)-4-methyl-5-(4-(trifluoromethyl)phenyl)oxazolidin-2-one (8j): A white solid: [α]D25 –72.3 (c 0.65, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 7.67 (d, J = 8.2 Hz, 2H), 7.44 (d, J = 8.2 Hz, 2H), 5.91 (br s, 1H), 5.77 (d, J = 7.7 Hz, 1H), 4.23–4.29 (m, 1H), 0.82 (d, J = 6.5 Hz, 3H); 13C-NMR (125 MHz, CDCl3) δ 158.9, 138.9, 130.8 (q, J = 32.5 Hz), 126.3, 125.6 (q, J = 3.8 Hz), 123.8 (q, J = 270.6 Hz), 80.1, 52.1, 17.6; HRMS (Q–TOF) m/z 246.0744 [(M + H)+, C11H11F3NO2 requires 246.0742].
(4S,5R)-5-heptyl-4-methyloxazolidin-2-one (8k): A colorless oil: [α]D25 +12.6 (c 0.34, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 6.06 (br s, 1H), 4.52–4.57 (m, 1H), 3.85–3.92 (m, 1H), 1.68–1.76 (m, 1H), 1.46–1.52 (m, 2H), 1.26–1.33 (m, 9H), 1.14 (d, J = 6.5 Hz, 3H), 0.87 (t, J = 6.9 Hz, 3H); 13C-NMR (125 MHz, CDCl3) δ 159.8, 80.2, 51.1, 31.7, 29.3, 29.10, 29.05, 25.8, 22.6, 15.9, 14.0; HRMS (Q–TOF) m/z 208.1314 [(M+Na)+, C10H19NNaO2 requires 208.1313].
(4S,5R)-5-butyl-4-methyloxazolidin-2-one (8l): A colorless oil: [α]D25 +14.8 (c 0.27, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 5.70 (br s, 1H), 4.53–4.58 (m, 1H), 3.86–3.92 (m, 1H), 1.70–1.77 (m, 1H), 1.48–1.56 (m, 2H), 1.31–1.41 (m, 3H), 1.16 (d, J = 6.5 Hz, 3H), 0.92 (t, J = 7.1 Hz, 3H); 13C-NMR (125 MHz, CDCl3) δ 159.6, 80.2, 51.1, 28.8, 27.9, 22.4, 15.9, 13.9; HRMS (Q–TOF) m/z 144.1032 [(M + H)+, C7H14NO2 requires 144.1025].

3.4. Synthesis of (–)-Cytoxazone

(2R,3R)-1-((R)-4-benzyl-2-thioxothiazolidin-3-yl)-4-(benzyloxy)-3-hydroxy-2-(4-methoxyphenyl)butan-1-one (11): A cooled (0 °C) solution of (R)-1-(4-benzyl-2-thioxothiazolidin-3-yl)-2-(4-methoxyphenyl)ethan-1-one 9 (118 mg, 0.330 mmol, 1.0 equiv.) in CH2Cl2 (3.3 mL, 0.1 M) was treated with titanium(IV) chloride (0.36 mL, 1.0 M in CH2Cl2, 0.36 mmol, 1.1 equiv.). After stirring for 30 min at 0 °C, i-Pr2NEt (0.14 mL, 0.83 mmol, 2.5 equiv.) was added dropwise and the resulting mixture was stirred for 2 h at 0 °C. 1-methyl-2-pyrrolidinone (NMP, 64 μL, 0.66 mmol, 2.0 equiv.) was added, and the resulting mixture was stirred for an additional 1 h and then cooled to −20 °C. 2-(benzyloxy)acetaldehyde 10 (148 mg, 0.990 mmol, 3 equiv.) in CH2Cl2 (2 mL) was added to the above enolate, and the resulting mixture was stirred for 1 h before it was quenched with the addition of saturated aqueous NH4Cl, and diluted with CH2Cl2. The layers were separated, and the aqueous layer was extracted with CH2Cl2. The combined organic layers were washed with saturated aqueous NaCl, dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by column chromatography (SiO2, 20% EtOAc/hexane) to provide an Evans syn aldol adduct 11 (124 mg, 74%) and a non-Evans syn aldol adduct (40 mg, 24%) as yellow oils: For 11: [α]D25 +8.3 (c 0.44, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 7.38–7.42 (m, 2H), 7.28–7.36 (m, 6H), 7.23–7.27 (m, 2H), 7.18–7.21 (m, 2H), 6.86–6.90 (m, 2H), 5.86 (d, J = 6.7 Hz, 1H), 5.25 (ddd, J = 10.5, 6.6, 3.8 Hz, 1H), 4.53 (s, 2H), 4.43 (dd, J = 12.2, 5.6 Hz, 1H), 3.80 (s, 3H), 3.57 (dd, J = 9.8, 5.3 Hz, 1H), 3.48 (dd, J = 9.8, 5.7 Hz, 1H), 3.08 (dd, J = 11.5, 7.3 Hz, 1H), 3.04 (dd, J = 13.5, 3.8 Hz, 1H), 2.83 (dd, J = 13.5, 10.7 Hz, 1H), 2.73 (dd, J = 11.5, 0.6 Hz, 1H); 13C-NMR (125 MHz, CDCl3) δ 200.7, 173.6, 159.1, 137.8, 136.4, 131.4, 129.3, 128.9, 128.4, 127.78, 127.76, 127.2, 125.5, 113.9, 73.5, 72.5, 71.9, 68.7, 55.2, 51.7, 36.6, 31.7; HRMS (Q–TOF) m/z 506.1458 [(M – H)+, C28H28NO4S2 requires 506.1460].
(4R,5R)-5-((benzyloxy)methyl)-4-phenyloxazolidin-2-one (12): A solution of 11 (28.5 mg, 0.056 mmol, 1.0 equiv.) in THF (1.4 mL, 0.04 M) was treated with Me3SiN3 (22.0 μL, 0.168 mmol, 3.0 equiv.) and the resulting mixture was heated to reflux at 90 °C. After stirring for 5 h at 90 °C, the resulting mixture was cooled to 25 °C, quenched with the addition of H2O and diluted with CH2Cl2. The layers were separated, and the aqueous layer was extracted with CH2Cl2. The combined organic layers were washed with saturated aqueous NaCl, dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by column chromatography (SiO2, gradient eluent: 25–50% EtOAc/hexane) to provide 12 (15.2 mg, 87%) as white oil: [α]D25 −13.3 (c 0.15, MeOH); 1H-NMR (500 MHz, CDCl3) δ 7.24–7.32 (m, 4H), 7.16–7.21 (m, 4H), 6.87–6.91 (m, 2H), 5.36 (br s, 1H), 4.98 (dt, J = 8.1, 5.8 Hz, 1H), 4.94 (d, J = 8.2 Hz, 1H), 4.25 (ABX, 2H, J = 11.7 Hz, Δν = 60.0 Hz), 3.83 (s, 3H), 3.37 (dd, J = 10.3, 6.1 Hz, 1H), 3.13 (dd, J = 10.3, 5.6 Hz, 1H); 13C-NMR (125 MHz, CDCl3) δ 160.0, 158.8, 137.4, 128.4, 128.3, 127.9, 127.8, 127.6, 114.1, 78.9, 73.4, 68.6, 57.8, 55.3; HRMS (Q–TOF) m/z 312.1225 [(M − H)+, C18H18NO4 requires 312.1236].
(−)-Cytoxazone (1): A solution of 12 (13 mg, 0.041 mmol, 1 equiv.) in EtOH (1.0 mL, 0.04 M) was treated with Pd/C (10%, 65 mg) and hydrogenated at 1 atm. After stirring for 1 h at 25 °C, the resulting mixture was filtered through a pad of Celite and concentrated in vacuo. The residue was purified by column chromatography (SiO2, 75% EtOAc/hexane) to provide (−)-cytoxazone (1, 8.7 mg, 95%) as a white oil whose spectral data were identical to those of the known synthetic 1 [40,41]: [α]D25 −72.6 (c 0.11, MeOH) vs [α]D25 −70.5 (c 0.8, MeOH) [40] and [α]D25 −70.9 (c 0.4, MeOH) [41]; 1H-NMR (500 MHz, DMSO-d6); δ 8.07 (br s, 1H), 7.14–7.16 (m, 2H), 6.92–6.94 (m, 2H), 5.90 (d, J = 8.3 Hz, 1H), 4.85 (t, J = 5.2 Hz, 1H), 4.70 (td, J = 8.0, 4.1 Hz, 1H), 3.74 (s, 3H), 2.91–3.00 (m, 2H); 13C-NMR (125 MHz, DMSO-d6) δ 159.1, 158.9, 129.3, 128.1, 113.7, 80.1, 61.1, 56.2, 55.2; HRMS (Q–TOF) m/z 246.0740 [(M + Na)+, C11H13NNaO4 requires 246.0742].

4. Conclusions

In conclusion, we investigated the scope and utility of a combination of the asymmetric aldol/Curtius protocol in the context of the synthesis of oxazolidin-2-one scaffolds bearing 4,5-two vicinal functionalities and their necessary stereogenic centers, due to its interesting structural motifs in natural products and diversity of pharmacological properties. The developed strategy also allows for a straightforward and concise asymmetric total synthesis of (−)-cytoxazone in only three steps, making it one of the shortest syntheses reported to date. Continued examination of the synthetic applications of the developed strategy in the synthesis of bioactive natural products and pharmaceuticals is in progress and will be disclosed in due course.

Supplementary Materials

The following are available online. Copies of 1H and 13C-NMR spectra of 1,4,8a–8l,11,12.

Author Contributions

Conceptualization, K.L.; methodology, H.C., H.J., and J.C.; formal analysis, H.C., H.J., and J.C.; investigation, H.C., H.J., and J.C.; resources, K.L.; data curation, K.L. and H.C.; writing—original draft preparation, K.L.; writing—review and editing, K.L.; visualization, H.C.; supervision, K.L.; project administration, K.L.; funding acquisition, K.L. All authors have read and agreed to the published version of the manuscript.

Funding

This research was supported by National Research Foundation of Korea (NRF) grants funded by the Korea government (MSIT; No.2020R1A2C1014355) and the 2018 Research Fund of the Catholic University of Korea.

Data Availability Statement

The data presented in this study are available in Supplementary Material.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Samples of the compounds 4,8a–8l are available from the authors.

References

  1. Slee, A.M.; Wuonola, M.A.; McRipley, R.J.; Zajac, L.; Zawada, M.J.; Bartholomew, P.T.; Gregory, W.A.; Forbes, M. Oxazolidinones, a New Class of Synthetic Antibacterial Agents: In Vitro and In Vivo Activities of DuP 105 and 721. Antimicrob. Agents Chemother. 1987, 31, 1791–1797. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Muller, M.; Schimz, K.L. Oxazolidinones: A novel class of antibiotics. Cell. Mol. Life Sci. 1999, 56, 280–285. [Google Scholar] [CrossRef] [PubMed]
  3. Marchese, A.; Schito, G.C. The oxazolidinones as a new family of antimicrobial agent. Clin. Microbiol. Infect. 2001, 7, 66–74. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Neu, H.C.; Novelli, A.; Saha, G.; Chin, N.X. In Vitro Acticities of Two Oxazolidinone Antimicrobial Agent, DuP 721 and DuP 105. Antimicrobal Agents Chemother. 1988, 32, 580–583. [Google Scholar] [CrossRef] [Green Version]
  5. Bozdogan, B.; Appelbaum, P.C. Oxazolidinones: Activity, mode of action, and mechanism of resistance. Int. J. Antimicrob. Agents 2004, 23, 113–119. [Google Scholar] [CrossRef]
  6. Naresh, A.; Rao, M.V.; Kotapalli, S.S.; Ummanni, R.; Rao, B.V. Oxazolidinone derivatives: Cytoxazone-linezolid hybrids induces apoptosis and senescence in DU145 prostate cells. Eur. J. Med. Chem. 2014, 80, 295–307. [Google Scholar] [CrossRef]
  7. Clemett, D.; Markham, A. Linezolid. Drugs 2000, 59, 815–827. [Google Scholar] [CrossRef]
  8. Ford, C.W.; Zurenko, G.E.; Barbachyn, M.R. The Discovery of Linezolid, the First Oxazolidinone Antibacterial Agent. Curr. Drug. Targets Infect. Disord. 2001, 1, 181–199. [Google Scholar] [CrossRef]
  9. Noskin, G.A.; Siddiqui, F.; Stosor, V.; Hacek, D.; Peterson, L.R. In Vitro Activities of Linezolid against Important Gram-positive Bacterial Pathogens Including Vancomycin-Resistant Enterococci. Antimicrob. Agents Chemother. 1999, 43, 2059–2062. [Google Scholar] [CrossRef] [Green Version]
  10. Burdette, S.D.; Trotman, R. Tedizolid: The first once-daily oxazolidinone class antibiotic. Clin. Infect. Dis. 2015, 61, 1315–1321. [Google Scholar]
  11. Evans, D.A.; Bartroli, J.; Shih, T.L. Enantioselective Aldol Condensations. 2. Erythro-Selective Chiral Aldol Condensations via Boron Enolates. J. Am. Chem. Soc. 1981, 103, 2127–2129. [Google Scholar] [CrossRef]
  12. Ager, D.J.; Prakash, I.; Schaad, D.R. 1,2-Amino alcohols and Their Heterocyclic Derivatives as Chiral Auxiliaries in Asymmetric synthesis. Chem. Rev. 1996, 96, 835–875. [Google Scholar] [CrossRef] [PubMed]
  13. Evans, D.A.; Wu, L.D.; Wiener, J.J.M.; Johnson, J.S.; Ripin, D.H.B.; Tedrow, J.S. A General Method for the Synthesis of Enantiomerically Pure β-Substituted, β-Amino Acids through α-Substituted Succinic Acid Derivatives. J. Org. Chem. 1999, 64, 6411–6417. [Google Scholar] [CrossRef]
  14. Dinsmore, C.J.; Mercer, S.P. Carboxylation and Mitsunobu Reaction of Amines to Give Carbamates: Retention vs Inversion of Configuration Is Substituent-Dependent. Org. Lett. 2004, 6, 2885–2888. [Google Scholar] [CrossRef]
  15. Yadav, G.D.; Pawar, S.V. Novelty of immobilized enzymatic synthesis of 3-ethyl-1,3-oxazolidin-2-one using 2-aminoalcohol and dimethyl carbonate: Mechanism and kinetic modeling of consecutive reactions. J. Mol. Catal. B Enzym. 2014, 109, 62–69. [Google Scholar] [CrossRef]
  16. Beattie, C.; North, M. Mechanistic Investigation of the Reaction of Epoxides with Heterocumulenes Catalysed by a Bimetallic Aluminium Salen Complex. Chem. Eur. J. 2014, 20, 8182–8188. [Google Scholar] [CrossRef]
  17. Castro-Osma, J.A.; Earlam, A.; Lara-Sánchez, A.; Otero, A.; North, M. Synthesis of Oxazolidinones from Epoxides and Isocyanates Catalysed by Aluminium Heteroscorpionate Complexes. Chem. Cat. Chem. 2016, 8, 2100–2108. [Google Scholar] [CrossRef]
  18. Fontana, F.; Chen, C.C.; Aggarwal, V.K. Palladium-Catalyzed Insertion of CO2 into Vinylaziridines: New Route to 5-Vinyloxazolidinones. Org. Lett. 2011, 13, 3454–3457. [Google Scholar] [CrossRef]
  19. Curtius, T. Ueber Stickstoffwasserstoffsäure (Azoimid) N3H. Ber. Dtsch. Chem. Ges. 1890, 23, 3023–3033. [Google Scholar] [CrossRef] [Green Version]
  20. Curtius, T. Hydrazide und Azide organischer Säuren. J. Prakt. Chem. 1894, 50, 275–294. [Google Scholar] [CrossRef] [Green Version]
  21. Scriven, E.F.V.; Turnbull, K. Azides: Their preparation and synthetic uses. Chem. Rev. 1988, 88, 297–368. [Google Scholar] [CrossRef]
  22. Shioiri, T.; Ninomiya, K.; Yamada, S. Diphenylphosphoryl Azide. A New Convenient Reagent for a Modified Curtius Reaction and for the Peptide Synthesis. J. Am. Chem. Soc. 1972, 94, 6203–6205. [Google Scholar] [CrossRef] [PubMed]
  23. Wolff, O.; Waldvogel, S.R. Reliable Protocol for the Large Scale Synthesis of Diphenylphosphoryl Azide (DPPA). Synthesis 2004, 1303–1305. [Google Scholar]
  24. Cowden, C.J.; Paterson, I. Asymmetric Aldol Reactions Using Boron Enolates. Org. React. 1997, 51, 1–200. [Google Scholar]
  25. Nagao, Y.; Kumagai, T.; Yamada, S.; Fujita, E.; Inoue, Y.; Nagase, Y.; Aoyagi, S.; Abe, T. Investigation of New Chiral 1,3- Oxazolidine-2-thiones: Analytical Separation and Optical Resolution of Racemic Carboxylic Acids and Amino Acids. J. Chem. Soc. Perkin Trans. 1 1985, 2361–2367. [Google Scholar] [CrossRef]
  26. Nagao, Y.; Yamada, S.; Kumagai, T.; Ochiai, M.; Fujita, E. Use of Chiral 1,3-Oxazolidine-2-thiones in the Diastereoselective Synthesis of Aldols. J. Chem. Soc. Chem. Commun. 1985, 1418–1419. [Google Scholar] [CrossRef]
  27. Crimmins, M.T.; King, B.W.; Tabet, E.A.; Chaudhary, K. Asymmetric Aldol Additions: Use of Titanium Tetrachloride and (−)-Sparteine for the Soft Enolization of N-Acyl Oxazolidinones, Oxazolidinethiones, and Thiazolidinethiones. J. Org. Chem. 2001, 66, 894–902. [Google Scholar] [CrossRef]
  28. Crimmins, M.T.; She, J. An Improved Procedure for Asymmetric Aldol Additions with N-Acyl Oxazolidinones, Oxazolidinethiones and Thiazolidinethiones. Synlett 2004, 1371–1374. [Google Scholar] [CrossRef] [Green Version]
  29. Crimmins, M.T.; Chaudhary, K. Titanium Enolates of Thiazolidinethione Chiral Auxiliaries: Versatile Tools for Asymmetric Aldol Additions. Org. Lett. 2000, 2, 775–777. [Google Scholar] [CrossRef]
  30. Choi, H.; Jang, H.; Kim, H.; Lee, K. Synthesis of γ-Lactones via the Kowalski Homologation Reaction: Protecting-Group-Free Divergent Total Syntheses of Eupomatilones-2,5,6, and 3-epi-Eupomatilone-6. Org. Lett. 2019, 21, 7857–7862. [Google Scholar] [CrossRef]
  31. Birkofer, L.; Wegner, P. Trimethylsilyl Azide. Org. Synth. 1970, 50, 107. [Google Scholar]
  32. Kakeya, H.; Morishita, M.; Kobinata, K.; Osono, M.; Ishizuka, M.; Osada, H. Isolation and biological activityof a novel cytokine modulator, cytoxazone. J. Antibiot. 1998, 51, 1126–1128. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Sakamoto, Y.; Shiraishi, A.; Seonhee, J.; Nakata, T. Stereoselective syntheses of cytoxazone, a novel cytokine modulator, and its stereoisomers. Tetrahedron Lett. 1999, 40, 4203–4206. [Google Scholar] [CrossRef]
  34. Kakeya, H.; Morishita, H.; Koshino, T.; Morita, K.; Kobayashi, K.; Osada, H. Cytoxazone: A Novel Cytokine Modulator Containing a 2-Oxazolidinone Ring Produced by Streptomyces sp. J. Org. Chem. 1999, 64, 1052–1053. [Google Scholar] [CrossRef] [PubMed]
  35. Carda, M.; González, F.; Sánchez, R.; Marco, J.A. Stereoselective synthesis of (−)-Cytoxazone. Tetrahedron Asymmetry 2002, 13, 1005–1010. [Google Scholar] [CrossRef]
  36. Carter, P.H.; LaPorte, J.R.; Scherle, P.A.; Decicco, C.P. A New Synthesis of Cytoxazone and Its Diastereomers Provides Key Initial SAR Information. Bioorg. Med. Chem. Lett. 2003, 13, 1237–1239. [Google Scholar] [CrossRef]
  37. Boruwa, J.; Borah, J.C.; Kalita, B.; Barua, N.C. Highly regioselective ring opening of epoxides using NaN3: A short and efficient synthesis of (–)-Cytoxazone. Tetrahedron Lett. 2004, 45, 7355–7358. [Google Scholar] [CrossRef]
  38. Davies, S.G.; Hughes, D.G.; Nicholson, R.L.; Smith, A.D.; Wright, A.J. Asymmetric synthesis of (4R,5R)-cytoxazone and (4R,5S)-epi-cytoxazone. Org. Biomol. Chem. 2004, 2, 1549–1553. [Google Scholar] [CrossRef]
  39. Venkataramasubramanian, V.; Kiran, I.N.C.; Sudalai, A. Proline-Catalyzed α-Aminooxylation of β-Amino Aldehydes: Access to Enantiomerically Pure syn- and anti-3-Amino-3-aryl-1,2-alkanediols. Synlett 2015, 26, 355–358. [Google Scholar]
  40. Lingamurthy, M.; Nalliboina, G.R.; Rao, M.V.; Rao, B.V.; Reddy, B.S.; Kumar, H.M.S. DDQ mediated stereoselective intermolecular benzylic CeN bond formation: Synthesis of (−)-cytoxazone, (−)-4-epi-cytoxazone and their analogues and immunological evaluation of their cytokine modulating activity. Tetrahedron 2017, 73, 1473–1481. [Google Scholar] [CrossRef]
  41. Hidasová, D.; Janák, M.; Jahn, E.; Císařová, I.; Jones, P.G.; Jahn, U. Diastereoselective Radical Couplings Enable the Asymmetric Synthesis of anti-β-Amino-α-hydroxy Carboxylic Acid Derivatives. Eur. J. Org. Chem. 2018, 5222–5230. [Google Scholar] [CrossRef]
Molecules 26 00597 sch001 550
Scheme 1. (a) Natural products and pharmaceuticals containing oxazolidin-2-ones (b) Conventional method towards the oxazolidin-2-ones (c) Proposed Strategy for the synthesis of the 4,5-disubstituted oxazolin-2-one framework.
Scheme 1. (a) Natural products and pharmaceuticals containing oxazolidin-2-ones (b) Conventional method towards the oxazolidin-2-ones (c) Proposed Strategy for the synthesis of the 4,5-disubstituted oxazolin-2-one framework.
Molecules 26 00597 sch001
Molecules 26 00597 sch002 550
Scheme 2. Synthesis of oxazolidin-2-one via the azidation/Curtius rearrangement sequence. a Isolated yield of major diastereomer. b Reaction conditions: 0.05–0.2 mmol of 3a–c. Bu3SnN3 (3 equiv., 30 min, entries 1–3), Me2AlN3 (3 equiv., 5 min, entries 4–6), Me3SiN3 (3 equiv., 3–5 h, entries 7–12), (n-Bu)4NN3 (3 equiv., 2 h, entries 13–15), NaN3 (10 equiv., 5 h, entries 16–18). c Commercially available. d Isolated yield. e No reaction was observed.
Scheme 2. Synthesis of oxazolidin-2-one via the azidation/Curtius rearrangement sequence. a Isolated yield of major diastereomer. b Reaction conditions: 0.05–0.2 mmol of 3a–c. Bu3SnN3 (3 equiv., 30 min, entries 1–3), Me2AlN3 (3 equiv., 5 min, entries 4–6), Me3SiN3 (3 equiv., 3–5 h, entries 7–12), (n-Bu)4NN3 (3 equiv., 2 h, entries 13–15), NaN3 (10 equiv., 5 h, entries 16–18). c Commercially available. d Isolated yield. e No reaction was observed.
Molecules 26 00597 sch002
Molecules 26 00597 sch003 550
Scheme 3. Synthesis of 4,5-disubstituted oxazolidin-2-ones from 5 and 6. a Isolated yield. b No reaction was observed. DPPA = diphenyl phosphoryl azide.
Scheme 3. Synthesis of 4,5-disubstituted oxazolidin-2-ones from 5 and 6. a Isolated yield. b No reaction was observed. DPPA = diphenyl phosphoryl azide.
Molecules 26 00597 sch003
Molecules 26 00597 sch004 550
Scheme 4. Substrate scope of the synthesis of 4,5-disubstituted oxazolidin-2-ones a. a All reactions were run on 0.1–0.2 mmol scale under the standard conditions. b Yields of isolated products after purification by flash chromatography.
Scheme 4. Substrate scope of the synthesis of 4,5-disubstituted oxazolidin-2-ones a. a All reactions were run on 0.1–0.2 mmol scale under the standard conditions. b Yields of isolated products after purification by flash chromatography.
Molecules 26 00597 sch004
Molecules 26 00597 sch005 550
Scheme 5. Concise total synthesis of (−)-cytoxazone (1). a A mixture of diastereomers (Evans syn: non-Evans syn = 3:1) was observed.
Scheme 5. Concise total synthesis of (−)-cytoxazone (1). a A mixture of diastereomers (Evans syn: non-Evans syn = 3:1) was observed.
Molecules 26 00597 sch005
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Choi, H.; Jang, H.; Choi, J.; Lee, K. Stereoselective Synthesis of Oxazolidin-2-ones via an Asymmetric Aldol/Curtius Reaction: Concise Total Synthesis of (−)-Cytoxazone. Molecules 2021, 26, 597. https://doi.org/10.3390/molecules26030597

AMA Style

Choi H, Jang H, Choi J, Lee K. Stereoselective Synthesis of Oxazolidin-2-ones via an Asymmetric Aldol/Curtius Reaction: Concise Total Synthesis of (−)-Cytoxazone. Molecules. 2021; 26(3):597. https://doi.org/10.3390/molecules26030597

Chicago/Turabian Style

Choi, Hosam, Hanho Jang, Joohee Choi, and Kiyoun Lee. 2021. "Stereoselective Synthesis of Oxazolidin-2-ones via an Asymmetric Aldol/Curtius Reaction: Concise Total Synthesis of (−)-Cytoxazone" Molecules 26, no. 3: 597. https://doi.org/10.3390/molecules26030597

Article Metrics

Back to TopTop